2012
2012
|
2011
2011
|
2010
2010
|
2009
2009
|
2008
2008
|
2007
2007
|
2006
2006
|
2005
2005
MAJOR MILESTONE ACHIEVEMENT IN AN ASSOCIATED COMPANY
2012.02.06
Jennerex and Lee's Pharmaceutical Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients with Advanced Liver Cancer
2011.11.30
Lee’s Pharm was honored at 2011’s Forbes Asia “Best Under A Billion” Award Ceremony
2011.11.22
Jennerex and Lee's Pharmaceutical Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer
2011.11.07
Submitted New Drug Application to the SFDA on Remodulin For Treatment of Pulmonary Arterial Hypertension
2011.09.12
Jennerex and Lee's Pharmaceutical Announce Publication of Interim Clinical Data of JX-594 Followed by Sorafenib Demonstrating Tumor Responses in Liver Cancer
2011.09.09
Jennerex and Lee's Pharmaceutical Announce the Publicatiion of Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic PoxvirusJX 594 to Tumors
2011.09.01
Jennerex and Lee's Pharmaceutical Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
2011.08.03
Completed Last Patient Follow-up in Clinical Study on Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy
2011.07.20
Jennerex and Lee's Pharmaceutical Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2011.05.23
Patients Enrollment completed in Clinical Study on Acetyl L-Carnitine Tablets for treatment of Peripheral Neuropathy
2011.05.12
Lee’s Pharma Announced the New Drug Registration of Natulan® for Hodgkin’s Disease in China
2011.05.09
Lee’s Pharm Announced the Completion of Phase I Study for its first-in-class drug Declotana®
2011.04.18
Patients Enrollment completed in Clinical Study on Propiverine Hydrochloride Modified Release Capsules for treatment of Urinary Incontinence
2011.04.13
Powder Pharmaceuticals Incorporated Enters into Agreement with Health-Chem Diagnostics, LLC obtaining Exclusive Manufacturing and Marketing Rights for TD Glucose in PRC, Hong Kong and other Asian Countries
2011.03.04
Propionyl-L-Carnitine Clinical Study Meets Primary and Secondary Endpoint of Treating Peripheral Arterial Diseases
2011.02.14
Approval received to initiate clinical study for Trittico®
2011.01.05
Lee’s Pharmaceutical Enters into Agreement with CID S.r.l. obtaining Exclusive Distribution of PTCA Balloon Catheters, Chrono Carbostent and Optima DES Carbostent in China
2010.12.30
Lee’s Pharm Accredited “Hong Kong Outstanding Enterprises 2010”
2010.12.06
Grand Opening of Headquarters of Powder Pharmaceuticals
2010.10.29
Grand Opening of Powder Pharmaceuticals Incorporated
2010.09.22
Patients Enrollment completed in Clinical Study on Propionyl-L-Carnitine Tablets for treatment of Peripheral Arterial Diseases
2010.07.02
UNITED THERAPEUTICS AND LEE’S PHARMACEUTICAL SIGN REMODULIN DISTRIBUTION AGREEMENT FOR CHINA
2010.07.02
Lee’s Pharm Accredited “Asia’s Best Companies 2010 – (China) Best Small Cap” Ranked 2nd
2010.06.09
Best Small-cap Company
2010.06.07
Lee’s Pharmaceutical Trading Debut
2010.05.17
Warm congratulations to the successful listing of Lee’s Pharm on the Main Board
2010.05.17
RECORDATI AND LEESPHARM ANNOUNCE PARTNERSHIP FOR ZANIDIP® IN CHINA
2010.03.15
Obtained Registration Certificate for Medical Device of Veloderm® in China
2010.01.29
Obtained Renewal of Imported Drug License for Co-dergocrine Mesylate in China
2010.01.15
Obtained Renewal of Imported Drug License for Ferplex® Iron Proteinsuccinylate Oral Solution in China
2010.01.14
Distribution Agreement signed to market Lercanidipine tablets in Hong Kong and Macau
2009.12.31
JENNEREX AND LEE’S PHARMACEUTICALS ANNOUNCE PARTNERSHIP FOR JX-594 IN CHINA
2009.11.23
Phase I Clinical Study on Antiplatelet Thrombolysin injection
2009.11.06
Lee's Pharmaceutical Enters into Agreement with Nippon Shinyaku A Move To Accelerate Market Diversification in China
2009.03.02
Lee's Pharmaceutical Establishes New R&D Centre at the Hong Kong Science Park To Bolster the Group's R&D Capabilities
2008.12.17
Anhui Government Official Visited Zhaoke Pharmaceutical (Hefei) Co. Ltd.
2008.12.22
New Drug Approval for Eyprotor® (Protein-free Calf Blood Extract Eye-gel) in China
2008.05.13
LEE'S SIGNED COLLABORATION AGREEMENT WITH NOVELOS
2007.12.19
SIGMA-TAU STRENGTHENS ITS PARTICIPATION IN LEE'S PHARMACEUTICALS
2007.09.20
Exclusive Distribution Agreement Signed for Aloxi® injection in China
2007.08.09
Completed the Pharmacokinetic Study of HIBOR® (Bemiparin Sodium)
2007.06.25
Distribution Agreement Signed with Italfarmaco of Italy for Serestill® in China
2007.06.18
Important milestones achieved in Clinical Studies of Stent & Balloon Catheter
2007.06.15
New Indication Approved for Cervicitis for Yallaferon
2006.10.18
Marketing Approval for Slounase® (Hemocoagulase) in China
2006.09.22
Approval to initiate a Clinical Trial for Hibor
2006.06.23
Approval for Clinical Study on Antiplatelet Thrombolysin injection
2006.02.20
Distribution agreement signed to market Propiverine Hydrochloride
2006.02.20
New Product Launch in Hong Kong - HIBOR® (Bemiparin Sodium)
2005.12.20
Completion of the Study of Yallaferon® in Cervicitis Patients
2005.12.20
New Drug Approval for Hemocoagulase snake venom
2005.10.17
Distribution of HORUS®S Coronary Stent
2005.09.28
New Indication Approved for Yallaferon®
2005.09.07
Distribution Agreement to market Somatostatin
2005.06.15
Complete patients recruitment for Cervicitis
2005.06.08
Completion of the Clinical Study of Eye-gel
2005.05.09
Market Isosorbide Mononitrate in HK and China
2005.03.29
Progress in Clinical Study of Eye-gel
2005.03.16
Good progress in Clinical Study in Cervicitis
2005.02.04
© Lee's Pharmaceutical Holdings Limited
Terms of Use
|
Privacy Statement
Designed by YSD